RxDoctor Payments Data

Kacey Patterson

Psychiatric/Mental Health · Saint Louis, MONPI 1619433125

Payments from drug & device makers

$1,994in general payments, 2019–2025

Across 106 payments — averaging $18.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$498
  • Alkermes, Inc.$308
  • AbbVie$281
  • Johnson & Johnson$251
  • Otsuka America Pharmaceutical, Inc.$232
  • E.r. Squibb & Sons, L.L.C.$196
  • plus $229 from 6 others

What the payments were for

  • Food & beverage$1,76589%
  • Education$22911%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,994 in reported general payments places this provider in the 65th percentile of 565 psychiatric/mental health providers in Missouri.

See all psychiatric/mental health providers in Missouri

Medicare billing

Part B allowed, 2024
$55,140
Medicare patients
91
Services billed
798

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate150$497,169
Abilify MaintenaAripiprazole48$128,055
AristadaAripiprazole Lauroxil37$96,555
Austedo XrDeutetrabenazine15$93,366
UzedyRisperidone15$46,436
LybalviOlanzapine/Samidorphan Malate23$36,868
SpravatoEsketamine Hcl24$26,347
VraylarCariprazine Hcl16$19,959
Clozapine160$17,566
Haloperidol Decanoate106$8,527
Fluphenazine Decanoate60$7,989
Paliperidone ErPaliperidone64$7,602
Aripiprazole162$6,346
Olanzapine339$6,263
Ziprasidone Hcl59$5,497

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Spravato$251$523,516174 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr, Uzedy$498$139,80230 claims
Alkermes, Inc.Aristada, Lybalvi$308$133,42360 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$232$128,05548 claims
AbbVieVraylar$281$19,95916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 565 psychiatric/mental health providers in Missouri.

Other psychiatric/mental health in Saint Louis

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →